Davis Polk advised the underwriters in connection with an SEC-registered Schedule B debt offering by KEXIM of $400 million aggregate principal amount of its 2.125% notes due 2021. The net proceeds from the offering will be used by KEXIM to extend loans to fund projects that promote the transition to low-carbon and climate-resilient growth.

KEXIM is an official export credit agency providing comprehensive export credit and guarantee programs to support Korean enterprises conducting overseas business.

Travers Smith corporate finance partner Richard Spedding and corporate finance senior associate Mark Anderson have advised Liberum Capital Limited (as nominated adviser and sole bookrunner) to Shield Therapeutics plc (“Shield Therapeutics”), on its £162 million IPO.

The IPO involved the conditional placing and subscription of £32.5 million of new ordinary shares and the issue of warrants to subscribe for ordinary shares, which, if exercised in full, would generate an additional £17.5 million of gross proceeds for Shield Therapeutics.

Herbert Smith Freehills is pleased to be advising Commonwealth Bank of Australia (CBA) on its issue of CommBank PERLS VIII Capital Notes and concurrent PERLS III Reinvestment Offer to raise approximately A$1.25 billion (with the ability to raise more or less), announced on 16 February 2016.

CBA is one of Australia’s leading providers of integrated financial services including retail banking, premium banking, business banking, institutional banking, funds management, superannuation, insurance, and investment and share broking products and services.

Travers Smith Corporate partner Richard Spedding and senior counsel Dan McNamee  have advised Canaccord Genuity and Investec, as joint bookrunners, on the block trade by Julian Dunkerton of shares held in SuperGroup Plc.

Julian Dunkerton, one of the founders of SuperGroup and its Product & Brand Director, sold 4.0 million ordinary shares in the company, representing approximately 4.9 per cent. of its issued share capital. The Placing Shares were placed at a price of 1,200 pence.

Linklaters LLP advised Eurex Clearing AG in connection with its new clearing model for U.S. clearing members and its approval by the U.S. Commodity Futures Trading Commission (CFTC) as a registered Derivatives Clearing Organization (DCO). Such clearing model and DCO registration will enable Eurex Clearing AG to offer its service “EurexOTC Clear” for the clearing of interest rate swaps in the United States in future and to further increase its international presence.

Cravath represented European Investment Bank in connection with its US$4 billion registered debt offering. European Investment Bank is a long-term financing institution of the European Union. The notes were listed on the Luxembourg Stock Exchange. The transaction closed on February 9, 2016.

The Cravath team included partner Philip J. Boeckman and associates Winnie Ling and Lawrence J. Verhelst.

Shearman & Sterling advised Barclays, J.P. Morgan and UBS on the refinancing of nearly all the existing indebtedness of Aguila S.A. and its subsidiaries (the Swissport Group) in connection with the acquisition of the Swissport Group by HNA Group Co. Ltd. HNA Group intends to continue operating the Swissport Group as a stand-alone business.

On 10 February 2016 Scandinavian Tobacco Group, the tobacco producer, was admitted to trading and official listing on Nasdaq Copenhagen. Plesner acted as legal advisor to JP Morgan, Nordea, Deutsche Bank and Carnegie in connection with the listing.

This week, health care institute Prinses Maxima centrum voor Kinderoncologie (PMCK) laid the foundation stone for the construction of the new building. The start of the construction is an important next step in the further development of research and health care for pedriatric onocolgy.

The new construction is partly financed by the issue of public notes. The Prinses Máxima Centrum is the first healthcare institution in years to obtain financing via a public notes issue in the Netherlands.
 

Noerr has advised ODDO SEYDLER BANK AG on the initial public offering of B.R.A.I.N. Biotechnology Research and Information Network AG. ODDO SEYDLER coordinated the transaction as the sole global coordinator and sole bookrunner. BRAIN AG is the first biotechnology company to go public on a German stock exchange in ten years.